Vemurafenib Active in Melanoma With Brain Metastases

Share this content:
Patients with metastatic melanoma and brain metastases achieved clinically meaningful response rates with vemurafenib.
Patients with metastatic melanoma and brain metastases achieved clinically meaningful response rates with vemurafenib.

Patients with metastatic melanoma and brain metastases achieved clinically meaningful response rates with vemurafenib without experiencing significant central nervous system toxicity, according to a study published in the Annals of Oncology.1

Vemurafenib is a kinase inhibitor indicated for the treatment of patients with BRAF V600E mutation-positive unresectable or metastatic melanoma. Researchers evaluated the overall response rate of vemurafenib among patients with brain metastases, previously treated or untreated.

For the international, phase 2 study, investigators enrolled 146 patients with BRAF V600-mutant melanoma. Of those, 90 with previously untreated brain metastases were assigned to cohort 1 and 56 with previously treated brain metastases were assigned to cohort 2. All participants received vemurafenib 960 mg orally twice daily until disease progression or unacceptable toxicity.

The intracranial best overall response rate in cohort 1 was 18%, including 2 complete and 14 partial responses. The extracranial best overall response rate was 33% in cohort 1 and 23% in cohort 2.

Median intracranial duration of response was 4.6 months in cohort 1 and 6.6 months in cohort 2 per independent review committee. Median extracranial duration of response was 7.7 months and 11.1 months for cohort 1 and cohort 2, respectively.

The median progression-free survival was 3.7 months in cohort 1 and 4.0 months in cohort 2; the median overall survival rates were 8.9 months and 9.6 months, respectively.

The incidence of toxicities was similar between the 2 cohorts with respect to type, grade, and frequency. Sixty-six percent of patients in cohort 1 had grade 3 to 4 adverse events vs 64% of those in cohort 2. Two patients died from adverse events cohort 1; 1 patient died from adverse events cohort 2.

RELATED: Can White Wine Consumption Lead to Melanoma?

Although these findings show clinically meaningful response rates in this population with poor prognosis, larger studies are needed to validate these results and to assess BRAF pathway inhibition in combination with immunotherapies and other treatment strategies.

Reference

  1. McArthur GA, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol. 2016 Dec 19. doi: 10.1093/annonc/mdw641 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters